Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Sarcoma, Ewing 1Lymphoproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Myeloid, Acute 1

Interventions

venetoclax 28Cytarabine 25Azacitidine 23Specimen Handling 21fludarabine 15Biopsy 13Injections 12Daunorubicin 11Cyclophosphamide 11fludarabine phosphate 10decitabine and cedazuridine drug combination 9Whole-Body Irradiation 9CPX-351 8Mycophenolic Acid 7Idarubicin 7Granulocyte Colony-Stimulating Factor 7Gemtuzumab 7ivosidenib 6Tacrolimus 6Stem Cell Transplantation 6Filgrastim 6Busulfan 6enasidenib 5X-Rays 5Melphalan 5Etoposide 5Decitabine 5Cyclosporine 5ruxolitinib 4olutasidenib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × etoposide phosphate × 30 days × Clear all
NCT02583893 2026-05-29

Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia

Thomas Jefferson University

Phase 2 Completed
39 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡